

Kamuvudine-9 (K9) in Diabetic Macular Edema

NCT07458061

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Dr. Bryan Strelow
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (13)

- Aged 18 years or older.
 - Diagnosis of diabetes mellitus, type 1 or 2 with non-proliferative or non-high risk proliferative diabetic retinopathy. Any one of the following will be considered sufficient evidence that diabetes is present:
 - Current regular use of insulin for the treatment of diabetes
 - Current regular use of oral hypoglycemic agents for the treatment of diabetes
 - DME based on investigator's clinical evaluation and evident on fundus photographs, fluorescein angiograms, or spectral domain-optical coherence tomography (SD-OCT)
- ... and 8 more (see full listing online)

Exclusion (30)

- Body weight \leq 55 kg.
 - Macular edema considered to be due to causes other than diabetes.
 - Proliferative diabetic retinopathy or iris neovascularization (including the anterior chamber angle) in the study eye.
 - Inability to follow the study protocol, based on the investigator's assessment.
 - Females who are pregnant or breastfeeding.
- ... and 25 more (see full listing online)

Locations (1 total)

Vistar Eye Center, Roanoke, Virginia, United States